Literature DB >> 4030502

Synthesis and antitumor activity of spergualin analogues. I. Chemical modification of 7-guanidino-3-hydroxyacyl moiety.

Y Umeda, M Moriguchi, H Kuroda, T Nakamura, H Iinuma, T Takeuchi, H Umezawa.   

Abstract

Many analogues and derivatives of an antitumor antibiotic, spergualin, were synthesized, and the relationships between the structure and the activity against mouse L-1210 tumor were studied. Both modification of the 15-hydroxyl group and alteration of chain-length of the omega-guanidinoacyl moiety affected the activity. 15-Deoxyspergualin (18, 1-amino-19-guanidino-11-hydroxy-4,9,12-triazanonadecane-10,13-d ion e) and its analogue 25 (1-amino-21-guanidino-11-hydroxy-4,9,12-triazauneicosane-10,13-dio ne) had strong activity, superior to that of spergualin.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4030502     DOI: 10.7164/antibiotics.38.886

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  12 in total

1.  Improved synthesis of 15-deoxyspergualin analogs using the Ugi multi-component reaction.

Authors:  Christopher G Evans; Matthew C Smith; James P Carolan; Jason E Gestwicki
Journal:  Bioorg Med Chem Lett       Date:  2011-03-01       Impact factor: 2.823

Review 2.  Heat shock protein 70 (hsp70) as an emerging drug target.

Authors:  Christopher G Evans; Lyra Chang; Jason E Gestwicki
Journal:  J Med Chem       Date:  2010-06-24       Impact factor: 7.446

Review 3.  Immunobiology and immunopharmacology of organ allograft rejection.

Authors:  M Suthanthiran; T B Strom
Journal:  J Clin Immunol       Date:  1995-07       Impact factor: 8.317

4.  Concise Synthesis of Spergualin-Inspired Molecules With Broad-Spectrum Antibiotic Activity.

Authors:  Victoria A Assimon; Hao Shao; Sylvie Garneau-Tsodikova; Jason E Gestwicki
Journal:  Medchemcomm       Date:  2015-03-30       Impact factor: 3.597

5.  Inhibition of cell growth through inactivation of eukaryotic translation initiation factor 5A (eIF5A) by deoxyspergualin.

Authors:  Kazuhiro Nishimura; Yuji Ohki; Tomomi Fukuchi-Shimogori; Kaori Sakata; Kan Saiga; Takanobu Beppu; Akira Shirahata; Keiko Kashiwagi; Kazuei Igarashi
Journal:  Biochem J       Date:  2002-05-01       Impact factor: 3.857

Review 6.  Pharmacological targeting of the Hsp70 chaperone.

Authors:  Srikanth Patury; Yoshinari Miyata; Jason E Gestwicki
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

7.  Deoxyspergualin, an immunosuppressant, in patients suffering from nephropathies with crescent formation: an open-label trial to evaluate safety and efficacy.

Authors:  Hirokazu Imai; Osamu Hotta; Mitsuhiro Yoshimura; Tsuneo Konta; Yoshiharu Tsubakihara; Masanobu Miyazaki; Chie Tomida; Masaki Kobayashi; Satoshi Suzuki; Hideo Shiiki; Atsushi Yamauchi; Hitoshi Yokoyama; Masato Nose
Journal:  Clin Exp Nephrol       Date:  2006-03       Impact factor: 2.801

8.  Phase I study of NKT-01.

Authors:  K Tamura; H Niitani; M Oguro; R Ohno; K Sanpi; H Majima; T Masaoka; I Kimura; J Inagaki; Y Suzuoki
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  Impact of 15-deoxyspergualin on effector cells in experimental autoimmune diseases of the nervous system in the Lewis rat.

Authors:  S Jung; K V Toyka; H P Hartung
Journal:  Clin Exp Immunol       Date:  1994-12       Impact factor: 4.330

10.  Myeloprotective activity of deoxyspergualin: influence on splenic colony-forming cell injury and antitumor activity of mitomycin C in mice.

Authors:  K Nemoto; Y Sugawara; M Ogino; T Mae; F Abe; T Takeuchi
Journal:  Jpn J Cancer Res       Date:  1992-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.